

Advances in the Care of Infants With Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome

Margarida Mascarenhas, MD, MMSc,^a Elisha M. Wachman, MD,^b Iyra Chandra, BS,^c Rachel Xue, BA,^d Leela Sarathy, MD,^e Davida M. Schiff, MD, MSc^a

A significant number of advances have been made in the last 5 years with respect to the identification, diagnosis, assessment, and management of infants with prenatal opioid exposure and neonatal opioid withdrawal syndrome (NOWS) from birth to early childhood. The primary objective of this review is to summarize major advances that will inform the clinical management of opioid-exposed newborns and provide an overview of NOWS care to promote the implementation of best practices. First, advances with respect to standardizing the clinical diagnosis of NOWS will be reviewed. Second, the most commonly used assessment strategies are discussed, with a focus on presenting new quality improvement and clinical trial data surrounding the use of the new function-based assessment Eat, Sleep, and Console approach. Third, both nonpharmacologic and pharmacologic treatment modalities are reviewed, highlighting clinical trials that have compared the use of higher calorie and low lactose formula, vibrating crib mattresses, morphine compared with methadone, buprenorphine compared with morphine or methadone, the use of ondansetron as a medication to prevent the need for NOWS opioid pharmacologic treatment, and the introduction of symptom-triggered dosing compared with scheduled dosing. Fourth, maternal, infant, environmental, and genetic factors that have been found to be associated with NOWS severity are highlighted. Finally, emerging recommendations on postdelivery hospitalization follow-up and developmental surveillance are presented, along with highlighting ongoing and needed areas of research to promote infant and family well-being for families impacted by opioid use.

Prenatal opioid exposure (POE) increased across the United States between 2000 and 2017, with rates of maternal opioid-related diagnoses reaching 8.2 per 1000 deliveries in 2017.^{1,2} The prevalence of neonatal opioid withdrawal syndrome (NOWS), a condition resulting from POE and also referred to as neonatal abstinence syndrome, has also increased the past 2 decades to 6.2 per 1000 live births in 2020.¹ Although emerging data from some states have shown a decline in the rates of NOWS between 2017 and 2021, rates vary widely across different US geographic regions, with New England and Appalachia being most heavily impacted, and rural areas seeing a faster increase (see Supplemental Table 5 and Supplemental Fig 1 for state-specific data).² POE disproportionately impacts lower-income and publicly-insured pregnant individuals.^{1,3} Polysubstance exposure and cooccurring substance use disorders in pregnant people with opioid use disorder (OUD) are common^{4,5} and occur in

abstract



^aDivisions of General Academic Pediatrics, and ^eNewborn Medicine, MassGeneral for Children, Boston, Massachusetts; ^bDepartment of Pediatrics, Boston Medical Center, and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts; ^cDana Farber Cancer Institute, Boston, Massachusetts; and ^dDepartment of Family Medicine, Boston Medical Center, Boston, Massachusetts

Drs Mascarenhas and Schiff performed the literature search, analyzed the findings, and drafted the initial manuscript; Dr Wachman drafted the initial manuscript; Ms Chandra and Ms Xue performed the literature search and drafted the initial manuscript; Dr Sarathy conceptualized and designed the study, and drafted the initial manuscript; and all authors reviewed and revised the manuscript, approved the final manuscript as submitted, and agree to be accountable for all aspects of the work.

DOI: <https://doi.org/10.1542/peds.2023-062871>

Accepted for publication Oct 16, 2023

Address correspondence to Davida M. Schiff, MD, MSc, Division of General Academic Pediatrics, MassGeneral Hospital for Children, 125 Nashua St, Suite 860, Boston, MA 02114. E-mail: davida.schiff@mgh.harvard.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2024 by the American Academy of Pediatrics

FUNDING: Dr Schiff received funding from the National Institute on Drug Abuse (K23DA048169). Dr Wachman received funding from the National Institute of Child Health and Human Development (R01HD096798). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

CONFLICT OF INTEREST DISCLOSURES: The authors have indicated they have no conflicts of interest relevant to this article to disclose.

To cite: Mascarenhas M, Wachman EM, Chandra I, et al. Advances in the Care of Infants With Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome. *Pediatrics*. 2024;153(2):e2023062871

up to two-thirds of deliveries,⁶ as are cooccurring mental health disorders resulting in frequent prenatal exposures to psychoactive medications.⁷

The objective of this state-of-the-art review is to highlight recent advances in the identification, diagnosis, assessment, and management of infants with POE during the delivery hospitalization and into early childhood. It aims to build upon the American Academy of Pediatrics (AAP) Clinical Report: Neonatal Opioid Withdrawal Syndrome and focus on emerging research published over the last 5 years to help guide pediatric clinical management of infants with POE.⁸ Ongoing and needed research to advance the care of families impacted by POE and infants experiencing NOWS are reviewed.

IDENTIFICATION AND DIAGNOSIS

Infants who develop physiologic dependence on opioids in utero experience an abrupt discontinuation of opioid exposure after delivery. This disruption results in a decrease in binding at opioid receptors located primarily in the central nervous system and gastrointestinal tract, and an increase in noradrenaline impacting the autonomic system.⁹ As a result, the clinical presentation of NOWS can include central nervous system irritability, gastrointestinal dysfunction, and autonomic hyperreactivity, resulting in alterations in sleep and wake cycles, irritability, feeding challenges, and overstimulation.⁸ A list of common clinical signs and symptoms is presented in Table 1.

Because the clinical signs of NOWS have similar features to other neonatal conditions including seizures, sepsis, respiratory distress syndromes, and hyperthyroidism, for infants with a confirmed history of POE who are not responding to initial NOWS management, a full evaluation and workup for other diagnoses should be considered.

With respect to prenatal identification, the preferred approach to identifying infants with in-utero opioid exposure at risk for NOWS is through the use of validated screening tools administered verbally or completed via written questionnaire during prenatal care and at delivery rather than toxicology testing.^{8,10} For infants, toxicology

testing should only be completed when it will inform clinical management; specific approaches toward perinatal toxicology testing have been reviewed in detail previously in the AAP Clinical Report.⁸ It is important for clinicians to be aware of pervasive racial/ethnic disparities in perinatal toxicology testing and the unique legal consequences related to substance use screening and testing with respect to mandated child protective services reporting in their state.^{11,12} Hospitals should establish clear guidelines on the actions after a positive verbal screen or aberrant test result, including that the risks and benefits of screening and testing are communicated clearly to the birth parents, and that consent is obtained before obtaining a biologic sample for toxicology testing.^{13,14}

The diagnosis of NOWS is made clinically, with standardized diagnostic criteria having just been recently proposed. An expert consensus panel was convened by the US Department of Health and Human Services using a modified Delphi method that identified 2 criteria required for the clinical diagnosis of NOWS:

- 1) exposure to opioids during pregnancy (identified via self-report or toxicology testing); and
- 2) the presence of at least 2 of the most common clinical signs of withdrawal including: Excessive crying, fragmented sleep, tremors, hypertonia, and gastrointestinal dysfunction.¹⁵

To date, there have been no published analyses of how diagnosis codes compare with this newly proposed definition, but the US Department of Health and Human Services definition was similar to the case definition used by Kuzniewicz and colleagues in their review of POE across multiple hospitals in the Kaiser Permanente network. Kuzniewicz found a positive predictive value of 85% when compared with infant International Classification of Diseases, Ninth and 10th Revision (ICD-10), codes for NOWS^{16,17}; however, the sensitivity of diagnosis codes for identifying POE was only 14% and NOWS was 32%.¹⁷

With respect to public health surveillance, in 2019, the Council of State and Territorial Epidemiologists' (CSTE) developed a definition that has been adopted by state

TABLE 1 Clinical Manifestations of NOWS			
Easy overstimulation, Hypersensitivity, or Hyperarousal	Alterations in Tone or Movements	Autonomic Dysfunction	Sleep and Wake Cycle Disturbances
Irritability	Hyperphagia	Sweating	Fragmented sleep
Excessive crying	Tremors	Sneezing	Short sleep cycles
Hypersensitivity to normal stimuli	Hyperreflexia	Mottled skin	Difficulty maintaining alert state
Uncoordinated feeding	Jitteriness	Fever	
Hyperphagia		Nasal stuffiness	
Excessive weight loss and poor weight gain		Tachypnea	
Vomiting		Frequent yawning	
Gassiness			
Diarrhea and loose stools			

public health departments that requires prenatal exposure to opioids, benzodiazepines, or barbiturates to be confirmed by neonatal toxicology testing. Elmore and colleagues found a low positive predictive value for the CSTE definition, with only 48% of clinical cases in a Florida data set identified; the toxicology testing requirement accounted for much of the discrepancy between ICD-10 codes and the CSTE definition.^{18,19}

PREPARING FOR DELIVERY HOSPITALIZATION

The delivery hospitalization can be a challenging time for birthing individuals with substance use disorders who often feel shame watching their newborn experience symptoms of withdrawal, perceive and/or experience stigma from hospital staff, and have anxiety surrounding possible child protective services involvement.²⁰ Prenatal consultation can help support families in preparing for the delivery hospitalization and identifying anticipated challenges after birth.^{21,22} Topics that are helpful to review include promoting a healthy pregnancy leading up to delivery, the short- and long-term impacts of POE, NOWS management and treatment, human milk feeding recommendations, toxicology testing guidelines, Plans of Safe Care, and preparing for child protective services involvement if indicated. Having clear policies and procedures established for the care of opioid-exposed dyads at delivery can help with counseling patients prenatally, standardizing care, and reducing bias. A list of guidelines that multidisciplinary teams should collaborate on to standardize approaches is included in Table 2.

To create a welcoming and positive experience for families during the delivery hospitalization, providers should use person-first language when talking with and about families impacted by POE. Examples of preferred and nonpreferred language are shown in Table 3.²³ To counteract the stigma and shame parents feel, antistigma and bias training for staff working on labor and delivery, postpartum, and newborn units can be implemented.^{24,25} These trainings should provide education around trauma-informed care, and reflective spaces should be made available to staff to debrief challenging and difficult experiences.²⁶

TABLE 3 Examples of Person-First, Nonstigmatizing Language	
Nonpreferred Terminology	Preferred Terminology
Infant terminology	Infant terminology
Addicted infant	• Infant with NOWS
Born addicted	• Substance-exposed newborn
NOWS infant	• Opioid-exposed newborn
Parental terminology	Parental terminology
Addict	• Person with OUD
Addicted mother	• Medication for OUD
Medication-assisted treatment	• Urine positive for nonprescribed substances
Dirty urine	
This is a nonexhaustive list intended to give a few examples of preferred and non-preferred terminology.	

ASSESSMENT AND MANAGEMENT OF NEWBORNS WITH POE

Location of Care

Rooming-in with the primary caregiver is the standard of care during the delivery hospitalization for all infants, including those with POE. Rooming-in models of care, either in the postpartum or pediatric inpatient unit, are associated with improved parental presence during the hospitalization, as well as an increase in breastfeeding initiation rates.²⁷ Numerous single-center studies and meta-analyses have examined the role of rooming-in on NOWS inpatient outcomes and have consistently demonstrated a reduction in the receipt of pharmacologic treatment by 20% to 60%, a decrease in the total opioid treatment days, and shortened length of hospitalization by 1 to 2 weeks when rooming-in is used compared with care in separate units, such as the NICU.^{27–29}

One potential barrier to rooming-in and a current source of wide variability in clinical practice is cardiorespiratory monitoring of infants requiring treatment with opioid medications.³⁰ Two single-center retrospective studies of infants undergoing treatment with either morphine or methadone found no significant differences in the incidence of cardiorespiratory adverse events compared with opioid-exposed infants who did not receive pharmacotherapy.^{31,32} In contrast, a randomized control trial of 117 infants receiving either

TABLE 2 Recommended Guidelines and Policies for Care of Opioid-Exposed Dyads and Multidisciplinary Teams	
Recommended clinical guidelines	Recommended hospital policies
Screening of birthing person for substance use	Indications for social work assessment and reporting to child protective services
Clinical rationales for toxicology testing for birthing person and newborn, including if and how consent will be obtained	Rooming-in and care location policies
NOWS assessment protocol	Parental engagement and visitation
NOWS nonpharmacologic and pharmacologic treatment algorithm	Jitteriness
Duration of observation for NOWS	
Breastfeeding recommendations in the setting of recent substance use	
Discharge criteria	

morphine or methadone who underwent cardiac monitoring reported a total of 13 adverse events including shallow breathing, bradycardia, oxygen desaturation, and lethargy, and 1 episode of apnea.³³

The coronavirus disease 2019 (COVID-19) pandemic also impacted rooming-in approaches. During the initial phase of the pandemic, a single-center study described how a policy requiring that parental caregivers stay on the postpartum unit decreased the number of transfers to the NICU, but did not decrease the overall length of hospitalization for NOWS.³⁴ Another statewide quality improvement (QI) collaborative showed that COVID-19 protocols hindered parental rooming-in and that infants had longer lengths of hospitalizations compared with a preCOVID-19 group.³⁵

NOWS Assessment Tools

Infants with POE should be monitored for signs of withdrawal every 3 to 4 hours during the delivery hospitalization, with assessments timed around when the infant is awake and/or nursing assessment times.⁸ These assessments should begin shortly after birth and for 4 to 7 days if no pharmacologic treatment is required, or continue for 24 to 48 hours after stopping medications if pharmacotherapy is indicated.

Several different NOWS assessment tools are currently available. Standardization of the approach selected and the following conditions should be prioritized.⁸ First, the infant should be kept in the room with the caregiver for assessments and the caregiver should be included in the assessment process to engender trust and engagement.⁸ Second, the assessment should occur after a feeding and consider the entire period since the last evaluation.

The 2 most commonly used approaches for assessing NOWS are the Finnegan Neonatal Abstinence Scoring Tool (FNAST) and the Eat, Sleep, and Console (ESC) assessment approach. The FNAST is a 21-item tool that characterizes all clinical signs possibly associated with neonatal withdrawal, with certain signs weighted on the basis of perceived severity. The original tool has since undergone several modifications and abbreviations.^{36–38} The ESC assessment approach was established by Grossman and colleagues to prioritize the functional needs of a newborn, focusing on 3 domains: The ability to eat the expected amount based on gestational and postnatal age, sleep undisturbed after a feeding for at least 1 hour, and being consoled within 10 minutes of soothing attempt.³⁹ Over the past 5 years, the ESC approach has been implemented across the country, particularly through statewide NOWS QI collaboratives in association with implementation of nonpharmacologic care bundles.^{40,41} The ESC approach with use of a standardized ESC care tool has been recently evaluated in a multicenter clinical trial using a stepped-wedged randomized design across 26 hospitals

that found that the ESC approach reduced time to infant discharge readiness by 6 days compared with the FNAST approach, without a significant increase in in-hospital safety events, unscheduled health care utilization, or nonaccidental trauma through 3 months postdischarge. Unlike QI efforts that coupled ESC implementation with pharmacotherapy changes, pharmacologic treatment protocols used by sites in the ESC-NOW trial were unchanged and still led to decrease in need for pharmacological treatment.⁴² Follow-up to assess long-term neurodevelopmental outcomes, growth, and family well-being through 24 months of age is ongoing.⁴³

NONPHARMACOLOGIC INTERVENTIONS

Environmental Modifications

First-line treatment of NOWS should prioritize nonpharmacologic interventions that are individually tailored to the infant's specific needs. The caregiver's functioning and ability to appropriately respond to their newborn's cues is critical to promote bonding and minimize further infant dysregulation while promoting optimal nonpharmacologic care.⁴⁴ Environmental modifications that have been used to decrease overstimulation include reducing noise and bright lights in the infant's room, swaddling and skin-to-skin time to reduce hyperarousal, and clustering of care times to limit disruptions to infant sleep. Recently, a randomized controlled trial using a vibrating crib mattress found a significant reduction in cumulative dose and length of pharmacotherapy in the subgroup of newborns that received <3 weeks of pharmacotherapy, but no reduction in overall need for pharmacotherapy or length of hospitalization.⁴⁵ A recent Cochrane review examined the efficacy of several novel nonpharmacological treatments of infants with POE. It included randomized control trials evaluating a vibrating mattress, prone positioning, waterbed, and a low stimulation nursery setting. They found that studies ranged from no evidence to very low certainty evidence of reducing length of hospitalization or need for pharmacologic therapy.⁴⁶

Feeding Interventions

Breastfeeding in the setting of NOWS has been associated with decreased severity and duration of symptoms,⁴⁷ and birthing parents motivated to breastfeed should be supported in their efforts, assuming they have no ongoing use at delivery, are engaged in prenatal care, and have no other contraindications to breastfeeding.^{48,49} In the case of formula feeding, there remains no consensus as to the first-line formula. Recent studies examining low lactose or partially hydrolyzed formulas compared with standard infant formulas have not demonstrated any differences in NOWS hospitalization outcomes.^{50–54} With respect to higher caloric density formula, although a recent randomized controlled trial found no significant differences

in NOWS outcomes in the high calorie versus usual care group, a multicenter QI initiative found that higher calorie formula did lead to reduction in length of stay, weight loss, and need for secondary pharmacologic agents.^{53,55} Hyperphagia, excessive weight loss, and poor weight gain in the setting of NOWS is common because of increased metabolic demand.^{56,57} For infants unable to meet minimal goal volumes, or with excessive weight loss despite adequate feeding, nasogastric supplementation should be considered until oral volume intake improves.

PHARMACOLOGIC INTERVENTIONS

When infants with POE continue to show signs of NOWS after maximizing nonpharmacologic options, the AAP supports the use of an opioid as the first-line pharmacologic agent.⁸ Table 4 highlights common dosing amounts and frequencies for the most studied medications when administered with standard dosing, as needed dosing, and weaning protocols.

Although a larger number of centers currently use morphine as their primary agent, several randomized controlled trials and a meta-analysis of methadone versus morphine have found improved short-term NOWS outcomes including

length of stay attributable to NOWS and length of treatment of methadone-treated infants.^{33,58} More recently, buprenorphine has been evaluated as a first-line agent with a reduction in length of stay attributable to NOWS compared with morphine and methadone in single-site studies.^{59,60} With respect to secondary agents, phenobarbital and clonidine are the most commonly used medications, with phenobarbital associated with a shorter length of hospitalization compared with clonidine, but longer total time on medication because of prolonged outpatient weans.⁶¹ A recent multi-site randomized trial evaluating the effect of maternal ondansetron administration during delivery and infant ondansetron after birth showed a nonstatistically significant reduction in infant opioid pharmacologic therapy in the ondansetron group compared with placebo.⁶² Regardless of choice of primary or secondary agent, a standardized protocol for dosing administration and weaning protocols has been associated with improved outcomes.⁶³ A multicenter study is ongoing to assess the impact of standard versus accelerated weaning on total opioid treatment days.⁶⁴

In the past 5 years, the most widely changing practice has been around the use of symptom-triggered, as needed dosing as opposed to standing, scheduled dosing. Both morphine and methadone have been examined in QI

TABLE 4 Pharmacologic Agents for Treatment of NOWS

Medication Name	Morphine	Methadone	Buprenorphine	Clonidine	Phenobarbital
Preferred use as primary or secondary agent	Primary	Primary	Primary	Secondary	Secondary
Standing dosing	0.3–1.0 mg/kg per d PO divided every 3–4 h	0.2–0.9 mg/kg per d PO divided every 6–12 h	13–40 mcg/kg per d SL divided in 3 doses	1 mcg/kg PO q4 h	Loading: 10–20 mg/kg per dose PO. Standing dosing: 5–8mg/kg per d PO in 1–2 divided doses
PRN dosing	0.03–0.05 mg/kg per dose PO every 3–4 h	0.07 mg/kg per dose PO q6–8 h	N/A	N/A	N/A
Weaning	10% per d down to 10%–20% of max dose	10% per d down to 10%–20% of max dose, or space interval	10% per d until at 10% of the max dose	Increase from q4 to q8 to q12 to off	20% every 3–7 d starting 2–3 d after primary opioid treatment has been weaned off
Monitoring levels	N/A	N/A	N/A	N/A	Therapeutic range: 15–30 mcg/mL
Advantages	Shorter half-life; more frequent dosing tailored to symptoms	Longer half-life, which may be better for more severe withdrawal	May be more advantageous for buprenorphine-exposed infants	No known risk for neurodevelopmental delays; no risk for infant sedation	May be better for polysubstance exposure; outpatient weaning is possible
Disadvantages	Longer length of treatment compared with methadone in several randomized controlled trials	Longer half-life makes it more difficult to tailor toward symptomatic dosing	Sublingual administration with high ethanol (30%) content	Blood pressure and heart rate monitoring during clonidine treatment because of risk of hypertension and arrhythmias	Risk of neurodevelopmental delays with prolonged exposure; high ethanol content in some preparations

N/A, not applicable; PO, by mouth; PRN, pro re nata - as needed; SL, sublingual.

projects, usually as part of nonpharmacologic care bundles and implementation of ESC protocols, with infants requiring on average 2 doses of medication.^{32,40,41,65,66} A multi-centered retrospective analysis compared the use of as-needed morphine to as-needed methadone and did not find any differences in short-term hospitalization outcomes.⁶⁷ A randomized controlled trial to assess symptom-based dosing compared with scheduled dosing has been proposed and is currently in development.⁶⁸

CONTRIBUTORS TO SEVERITY OF NOWS PRESENTATION

Several important studies have furthered our understanding of contributors to NOWS severity, which has been heterogeneously defined in studies to date.^{69,70} Co-exposures to other substances and medications, maternal and neonatal characteristics, genetic factors, and postnatal environmental factors have all been found to be associated with NOWS severity, and key associations with recently published data are summarized below:

Medications to Treat OUD

One recent study utilizing sophisticated matching techniques to compare prenatal buprenorphine versus methadone use among a national cohort of pregnant people with OUD found a significantly reduced percentage of infants receiving a diagnosis of NOWS among buprenorphine-exposed neonates.⁶⁹ Despite these findings, the use of medications to treat OUD during pregnancy should be individualized; furthermore, most of these studies were performed before the rise of nonprescribed fentanyl in the drug supply, for which methadone is often preferred to stabilize patients.⁷⁰

Prescribed Opioid Medications

For prescribed opioid medications, Straub and colleagues created 6 different opioid-prescribing trajectories and found that NOWS risk increased from exposure to higher doses of opioids, as well as cumulative exposure, one of the first large-scale studies to examine the risk of NOWS from chronic prescription opioid use.⁷¹

Polysubstance Exposure

Coexposure to nonprescribed substances, including cocaine and cannabis, is strongly associated with more severe NOWS.^{72–74}

Psychiatric Medication Exposure

Many different classes of psychiatric medications have been found to be associated with more severe NOWS, including selective serotonin reuptake inhibitors,^{75,76} benzodiazepines,⁷⁷ and gabapentin.⁷⁴ Exposure to 2 or more psychiatric medication types is also associated with more severe NOWS.⁶

Prenatal Care

Engagement in prenatal care was found to mediate the relationship between medication for opioid use disorder and NOWS severity in a sample from 30 hospitals across the United States.⁷³

Genetic and Epigenetic Factors

In addition to clinical and environmental factors, both genetic variation and epigenetic modifications are being studied to better understand their contribution to NOWS severity. In a recent, genomewide association study, a locus on chromosome 7 downstream of sorting nexin 13 was associated with receipt of pharmacologic treatment.⁷⁸ Additional studies have looked at epigenetic modification and the association with NOWS severity and found differences in DNA methylation levels in infants who received more pharmacotherapy for NOWS and differences in methylation levels within placental tissue associated with infant receipt of pharmacologic treatment.^{79–81}

DISCHARGE PLANNING

A clinical readiness checklist can be used to assess whether an infant experiencing NOWS is ready to be safely discharged. Common elements include resolution of withdrawal symptoms, a period of 24 to 48 hours of observation after stopping pharmacological treatment, adequate feeding and weight gain, safety assessment of the caregivers, completing a plan of safe care, and placing referrals for outpatient follow-up.⁸ A discharge bundle implemented at a single site in Tennessee found significant improvements in referrals to recommended developmental surveillance programs, home visiting, and specialist referrals.⁸²

OUTPATIENT MANAGEMENT

Once the immediate withdrawal signs of NOWS have passed, there is a clear drop in evidence-based practice and recommendations. Yet, recent studies looking at the first year after birth have identified concern for increased risks of infant morbidity and mortality including: A lower rate of attendance at well-child visits⁸³ and at recommended developmental follow-up services,⁸⁴ higher rate of emergency department visits^{85,86} and hospital admissions,^{85–87} and increased risk of mortality for infants with POE or NOWS.^{88,89}

The evidence around long-term outcomes is not only scarcer, but also has more limitations, which make the interpretation of the findings more difficult.^{90,91} Over the past 5 years, a handful of meta-analysis and prospective studies have aimed to evaluate the impact of POE. First, two meta-analyses compared POE with non-exposed controls (1 included 26 studies going back to 1979, the other with 16 studies starting in 1993) and found motor and cognitive delays for infants and preschool-aged children.^{92,93}

For both of these studies, limitations include failure to differentiate exposure to methadone or buprenorphine from heroin, not all studies adjusted for socioeconomic status, and adjusting for other prenatal exposures such as nicotine, alcohol, or polydrug exposures was not discussed. Schwartz and colleagues performed a meta-analysis assessing POE and attention-deficit/hyperactivity disorder symptoms and identified a positive association in preschool- and school-aged children compared with non-exposed controls.⁹⁴ Although the studies included in Schwartz's analyses accounted for polysubstance exposures, only half accounted for socioeconomic or postnatal environmental factors, including out-of-home placement. Czynski and colleagues published the results of neurodevelopmental assessments on infants requiring pharmacologic treatment of NOWS who received either morphine or methadone as part of a randomized clinical trial and found no differences across 3 neurodevelopmental scales used between discharge and 18 months by NOWS treatment type.⁹⁵ There are currently several rigorously designed, large-scale, clinical trials and longitudinal studies focusing on long-term outcomes for infants with POE and its management on different child outcomes, including development, growth, and morbidity, that aim to address the limitations of previously published studies.^{43,90,91,96}

Developmental Surveillance

Because of the increased risk of developmental delays, it is recommended that infants with POE are formally assessed for developmental concerns.⁹⁷ Newborn developmental follow-up clinics are available at some centers to provide episodic developmental screening and testing with multidisciplinary team supports.⁸ Similarly, infants with POE can benefit from early intervention services, which are available across the country for infants and toddlers at risk for developmental delays.⁹⁸ In some states, a diagnosis of NOWS is considered a qualifying condition to receive services for a full year,⁹⁹ but rates of engagement among eligible infants remain low.⁸⁴

Hepatitis C

For children whose birth parent had a detectable hepatitis C viral load during pregnancy, guidelines recommend testing with hepatitis C virus (HCV) antibody test to be first completed at 18 months of age. The timing of this test avoids potential false positives from circulating maternal antibodies.¹⁰⁰ New recommendations by the Centers for Disease Control and Prevention have proposed that testing for HCV infection be conducted between 2 and 6 months of age with nucleic acid testing for HCV RNA to allow for proper referral and follow-up with providers experienced in pediatric hepatitis C management.¹⁰¹ Regardless of the time of testing, currently, treatment of hepatitis C is only approved after 3 years of age.^{100,101}

Vision Screening

Infants with POE may have an increased risk of ocular abnormalities, with the most common being strabismus, nystagmus, and reduced visual acuity. There is also evidence that changes in the amplitude, latency, and response in visual evoked potentials testing can be detected as early as the neonatal period and persist later in childhood.¹⁰² Early detection of vision disorders is essential to provide prompt ophthalmologic treatment and to improve developmental outcomes.

AREAS FOR FUTURE RESEARCH TO ADVANCE CLINICAL PRACTICE

The present research and practice improvement landscape with respect to POE is an exciting one, with many clinical advances made in the past decade. Large studies are being conducted across the country assessing novel NOWS treatment modalities and the impacts of POE on children and families.^{68,90,91,96}

As the medical community comes to consensus around the best clinical diagnosis for NOWS, there remains a need to further align it with surveillance metrics used by state public health departments and determine the appropriate diagnostic codes for infants with POE who do not necessarily experience signs of withdrawal to inform studies assessing long-term outcomes of in-utero exposures. Incorporating type of POE, including prescribed or administered opioids compared with nonprescribed use (eg, polysubstance use and newer exposures including fentanyl and xylazine), is crucial to accurately describe and quantify the impact of prenatal exposures. Additionally, efforts should be made to remove stigmatizing or inaccurate language from ICD-10 codes; for example, the 2 recommended codes P96.1 (neonatal withdrawal symptoms from maternal use of drugs of addiction) and P04.49 (newborn affected by maternal use of other drugs of addiction) do not offer a nonstigmatizing option when POE results from maternal use of medications to treat OUD, not a "drug of addiction."¹⁰³

With respect to assessment, with adequate feeding becoming a criterion for adequately managed withdrawal in the increasingly used ESC approach, optimal feeding support bundles are needed, including supporting parents who desire to provide breast milk in addition to formula options. Additionally, with the current shift to function-based assessments, studies incorporating the ability of the caregiver to respond to an infant's needs will be beneficial to expanding individualized nonpharmacologic options. Reducing subjectivity in applying assessment tools and further development of objective measures of withdrawal can further help with ongoing assessment standardization.

With respect to pharmacologic treatment, the growing popularity and success of as-needed dosing for NOWS

treatment in reducing prolonged iatrogenic opioid exposures warrants an evaluation of its short-term and long-term effects, isolated from the implementation of other QI bundles. Studies should incorporate the recommended core set of Nows outcomes (need for pharmacologic treatment, total dose and duration of opioid treatment, need for adjunctive therapy, and length of hospitalization) to standardize measures of Nows severity reported.^{104,105}

Finally, with respect to long-term outcomes, ongoing studies aim to fill our gap in understanding around the potential neurodevelopmental impacts of POE and different Nows management approaches. Although there is potential for major breakthroughs in understanding the effects of opioids on the developing brain, ensuring the scope of focus is expanded to include the interpersonal, intrapersonal, and environmental factors that contribute to child development and well-being, is critical to identifying the supports needed to improve outcomes for opioid-exposed dyads, including improving engagement in the recommended developmental surveillance and treatments.

ABBREVIATIONS

AAP: American Academy of Pediatrics
 COVID-19: coronavirus disease 2019
 CSTE: Council of State and Territorial Epidemiologists
 ESC: Eat, Sleep, and Console
 FNASt: Finnegan Neonatal Abstinence Scoring Tool
 HCV: hepatitis C virus
 ICD-10: International Classification of Diseases, 10th Revision
 Nows: neonatal opioid withdrawal syndrome
 OUD: opioid use disorder
 POE: prenatal opioid exposure
 QI: quality improvement

REFERENCES

- Hirai AH, Ko JY, Owens PL, Stocks C, Patrick SW. Neonatal abstinence syndrome and maternal opioid-related diagnoses in the United States, 2010–2017. *JAMA*. 2021;325(2):146–155
- Agency for Healthcare Research and Quality. Health Care Cost and Utilization Project (HCUP) fast stats. Available at: <https://datatools.ahrq.gov/hcup-fast-stats/?tab=special-emphasis&dash=83>. Accessed September 10, 2023
- Strahan AE, Guy GP Jr, Bohm M, Frey M, Ko JY. Neonatal abstinence syndrome incidence and health care costs in the United States, 2016. *JAMA Pediatr*. 2020;174(2):200–202
- Jarlenski MP, Paul NC, Krans EE. Polysubstance use among pregnant women with opioid use disorder in the United States, 2007–2016. *Obstet Gynecol*. 2020;136(3):556–564
- Tran EL, England LJ, Park Y, Denny CH, Kim SY. Systematic review: polysubstance prevalence estimates reported during pregnancy, United States, 2009–2020. *Matern Child Health J*. 2023;27(3):426–458
- Wachman EM, Warden AH, Thomas Z, et al. Impact of psychiatric medication co-exposure on neonatal abstinence syndrome severity. *Drug Alcohol Depend*. 2018;192:45–50
- Krans EE, Kim JY, James AE III, Kelley D, Jarlenski MP. Medication-assisted treatment use among pregnant women with opioid use disorder. *Obstet Gynecol*. 2019;133(5):943–951
- Patrick SW, Barfield WD, Poindexter BB. Committee on Fetus and Newborn; Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. *Pediatrics*. 2020;146(5):e2020029074
- Kocherlakota P. Neonatal abstinence syndrome. *Pediatrics*. 2014;134(2):e547–e561
- Committee on Obstetric Practice American Society of Addiction Medicine. ACOG Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Available at: www.integration.samhsa.gov/. Accessed April 28, 2023
- Murosko D, Paul K, Barfield WD, Montoya-Williams D, Parga-Belinkie J. Equity in policies regarding urine drug testing in infants. *NeoReviews*. 2022;23(11):788–795
- Cohen S, Nielsen T, Chou JH, et al. Disparities in maternal-infant drug testing, social work assessment, and custody at 5 hospitals. *Acad Pediatr*. 2023;23(6):1268–1275
- United States Supreme Court. *Ferguson v. Charleston*, 532 U.S. 67. 2001
- American Society of Addiction Medicine. ASAM public policy: substance use and substance use disorder among pregnant and postpartum people. Available at: <https://www.asam.org/advocacy/public-policy-statements/details/public-policy-statements/2022/10/12/substance-use-and-substance-use-disorder-among-pregnant-and-postpartum-people>. Accessed April 30, 2023
- Jilani SM, Jones HE, Grossman M, et al. Standardizing the clinical definition of opioid withdrawal in the neonate. *J Pediatr*. 2022;243:33–39.e1
- Heslin KC, Owens PL, Karaca Z, Barrett ML, Moore BJ, Elixhauser A. Trends in opioid-related inpatient stays shifted after the US transitioned to ICD-10-CM diagnosis coding in 2015. *Med Care*. 2017;55(11):918–923
- Kuzniewicz MW, Campbell CI, Li S, et al. Accuracy of diagnostic codes for prenatal opioid exposure and neonatal opioid withdrawal syndrome. *J Perinatol*. 2023;43(3):293–299
- Council of State and Territorial Epidemiologists (CSTE). Neonatal abstinence syndrome (NAS) standardized surveillance case definition position statement. Available at: https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/2019ps/19-MCH-01_NAS_updated_5.7.19.pdf. Accessed February 26, 2023
- Elmore AL, Tanner JP, Lowry J, et al. Diagnosis codes and case definitions for neonatal abstinence syndrome. *Pediatrics*. 2020;146(3):e20200567
- Schiff DM, Work EC, Muftu S, et al. “You have to take this medication, but then you get punished for taking it”: lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period. *J Subst Abuse Treat*. 2022;139:108765

21. Frazer Z, McConnell K, Jansson LM. Treatment for substance use disorders in pregnant women: motivators and barriers. *Drug Alcohol Depend.* 2019;205:107652
22. Buczkowski A, Avidan O, Cox D, Craig A. The parental experience of newborns with neonatal abstinence syndrome across inpatient care settings: a qualitative study. *J Addict Med.* 2020;14(5):e183–e187
23. Alinsky RH, Hadland SE, Quigley J, Patrick SW. Committee on Substance Use and Prevention. Recommended terminology for substance use disorders in the care of children, adolescents, young adults, and families. *Pediatrics.* 2022;149(6):2022057529
24. Institute for Perinatal Quality Improvement. SPEAK UP Program. Available at: <https://www.perinatalqi.org/page/SPEAKUP>. Accessed August 22, 2023
25. Marcellus L, Poag E. Adding to our practice toolkit: using the ACTS script to address stigmatizing peer behaviors in the context of maternal substance use. *Neonatal Netw.* 2016;35(5):327–332
26. Substance Abuse Mental Health Services Administration. TIP 57: trauma-informed care in behavioral health services. Available at: <https://store.samhsa.gov/product/TIP-57-Trauma-Informed-Care-in-Behavioral-Health-Services/SMA14-4816>. Accessed July 18, 2018.
27. MacMillan KDL, Rendon CP, Verma K, Riblet N, Washer DB, Volpe Holmes A. Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. *JAMA Pediatr.* 2018;172(4):345–351
28. Ryan G, Dooley J, Gerber Finn L, Kelly L. Nonpharmacological management of neonatal abstinence syndrome: a review of the literature. *J Matern Fetal Neonatal Med.* 2019;32(10):1735–1740
29. Newman AI, Mauer-Vakil D, Coe H, et al. Rooming-in for infants at risk for neonatal abstinence syndrome: outcomes 5 years following its introduction as the standard of care at one hospital. *Am J Perinatol.* 2022;39(8):897–903
30. Joshi NS, Flaherman VJ, Halpern-Felsher B, Chung EK, Congdon JL, Lee HC. Admission and care practices in United States well newborn nurseries. *Hosp Pediatr.* 2023;13(3):208–216
31. Davala S, Hansbury A, Miller M, Boateng J, Shrestha H, Wachman EM. Pilot study comparing adverse cardiorespiratory events among pharmacologically and nonpharmacologically treated infants undergoing monitoring for neonatal abstinence syndrome. *J Pediatr X.* 2020;3:100027
32. Spence K, Boedeker R, Harhausen M, Kaushal G, Buchanan P, Josephsen J. Avoiding NICU transfers for newborns with neonatal opioid withdrawal syndrome (NOWS): a quality improvement initiative to manage NOWS on the mother–baby unit. *J Addict Med.* 2020;14(5):401–408
33. Davis JM, Shenberger J, Terrin N, et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. *JAMA Pediatr.* 2018;172(8):741–748
34. Cooney T, Cote U, Bergen E, Dampier A, Inkila L, Edwards C. Effects on Neonatal abstinence syndrome of parental caregivers' ability to leave the postpartum unit during the COVID-19 pandemic. *Nurs Womens Health.* 2023;27(4):283–290
35. MacMillan KDL, Morrison TM, Melvin P, Diop H, Gupta M, Wachman EM. Impact of coronavirus disease 2019 on hospital care for neonatal opioid withdrawal syndrome. *J Pediatr.* 2022;245:47–55
36. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. *Addict Dis.* 1975;2(1-2):141–158
37. Devlin LA, Breeze JL, Terrin N, et al. Association of a simplified Finnegan Neonatal Abstinence Scoring Tool with the need for pharmacologic treatment for neonatal abstinence syndrome. *JAMA Netw Open.* 2020;3(4):e202275
38. Chervoneva I, Adeniyi-Jones SC, Blanco F, Kraft WK. Development of an abbreviated symptom score for the neonatal abstinence syndrome. *J Perinatol.* 2020;40(7):1031–1040
39. Grossman MR, Lipshaw MJ, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. *Hosp Pediatr.* 2018;8(1):1–6
40. Wachman EM, Houghton M, Melvin P, et al. A quality improvement initiative to implement the eat, sleep, console neonatal opioid withdrawal syndrome care tool in Massachusetts' PNQIN collaborative. *J Perinatol.* 2020;40(10):1560–1569
41. Hwang SS, Weikel B, Adams J, et al. The Colorado Hospitals Substance Exposed Newborn Quality Improvement Collaborative: standardization of care for opioid-exposed newborns shortens length of stay and reduces number of infants requiring opiate therapy. *Hosp Pediatr.* 2020;10(9):783–791
42. Young LW, Ounpraseuth ST, Merhar SL, et al. ACT NOW Collaborative. Eat, Sleep, Console approach or usual care for neonatal opioid withdrawal. *N Engl J Med.* 2023;388(25):2326–2337
43. Young LW, Ounpraseuth S, Merhar SL, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the National Institutes of Health Environmental influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Network. Eating, sleeping, consoling for neonatal opioid withdrawal (ESC-NOW): a function-based assessment and management approach study protocol for a multicenter, stepped-wedge randomized controlled trial. *Trials.* 2022;23(1):638
44. Velez ML, Jordan C, Jansson LM. Reconceptualizing nonpharmacologic approaches to neonatal abstinence syndrome (NAS) and neonatal opioid withdrawal syndrome (NOWS): a theoretical and evidence-based approach. Part II: the clinical application of nonpharmacologic care for NAS/NOWS. *Neurotoxicol Teratol.* 2021;88:107032
45. Bloch-Salisbury E, Wilson JD, Rodríguez N, et al. Efficacy of a vibrating crib mattress to reduce pharmacologic treatment in opioid-exposed newborns: a randomized clinical trial. *JAMA Pediatr.* 2023;177(7):665–674
46. Pahl A, Young L, Buus-Frank ME, Marcellus L, Soll R. Nonpharmacological care for opioid withdrawal in newborns. *Cochrane Database Syst Rev.* 2020;12(12):CD013217
47. Favara MT, Carola D, Jensen E, et al. Maternal breast milk feeding and length of treatment in infants with neonatal abstinence syndrome. *J Perinatol.* 2019;39(6):876–882
48. Harris M, Schiff DM, Saia K, Muftu S, et al. Academy of breastfeeding medicine clinical protocol #21: Breastfeeding in the setting of substance use and substance use disorder. *Rev Breastfeed Med.* 2023;18(10):715–733
49. Meek JY, Noble L. Section on Breastfeeding. Policy statement: breastfeeding and the use of human milk. *Pediatrics.* 2022;150(1):e2022057988

50. Alsaleem M, Dusin J, Akangire G. Effect of low lactose formula on the short-term outcomes of neonatal abstinence syndrome: a systematic review. *Glob Pediatr Health*. 2021;8:X211035258
51. Pandey R, Kanike N, Ibrahim M, et al. Lactose-free infant formula does not change outcomes of neonatal abstinence syndrome (NAS): a randomized clinical trial. *J Perinatol*. 2021;41(3):598–605
52. Lembeck AL, Tuttle D, Locke R, et al. Breastfeeding and formula selection in neonatal abstinence syndrome. *Am J Perinatol*. 2021;38(14):1488–1493
53. Kaplan HC, Kuhnell P, Walsh MC, et al. Ohio Perinatal Quality Collaborative. Orchestrated testing of formula type to reduce length of stay in neonatal abstinence syndrome. *Pediatrics*. 2020;146(4):e20190914
54. Alsaleem M, Berkelhamer SK, Wilding GE, Miller LM, Reynolds AM. Effects of partially hydrolyzed formula on severity and outcomes of neonatal abstinence syndrome. *Am J Perinatol*. 2020;37(11):1177–1182
55. Bogen DL, Hanusa BH, Baker R, Medoff-Cooper B, Cohan B. Randomized clinical trial of standard- versus high-calorie formula for methadone-exposed infants: a feasibility study. *Hosp Pediatr*. 2018;8(1):7–14
56. Cheng FY, Shabanova V, Berkwitz AK, Grossman MR. Early weight loss percentile curves and feeding practices in opioid-exposed infants. *Hosp Pediatr*. 2022;12(10):857–866
57. Yen E, Maron JL. Aberrant feeding and growth in neonates with prenatal opioid exposure: evidence of neuromodulation and behavioral changes. *Front Pediatr*. 2022;9:805763
58. Sutter MB, Watson H, Yonke N, Weitzen S, Leeman L. Morphine versus methadone for neonatal opioid withdrawal syndrome: a randomized controlled pilot study. *BMC Pediatr*. 2022;22(1):345
59. Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. *N Engl J Med*. 2017;376(24):2341–2348
60. Hall ES, Rice WR, Folger AT, Wexelblatt SL. Comparison of neonatal abstinence syndrome treatment with sublingual buprenorphine versus conventional opioids. *Am J Perinatol*. 2018;35(4):405–412
61. Brusseau C, Burnette T, Heidel RE. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. *J Perinatol*. 2020;40(7):1050–1055
62. Peltz G, Jansson LM, Adeniyi-Jones S, et al. Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial. *J Perinatol*. 2023;43(3):271–276
63. Hall ES, Wexelblatt SL, Crowley M, et al. OCHNAS Consortium. Implementation of a neonatal abstinence syndrome weaning protocol: a multicenter cohort study. *Pediatrics*. 2015;136(4):e803–e810
64. ClinicalTrials.gov. Trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS). Available at: <https://clinicaltrials.gov/ct2/show/NCT04214834>. Accessed May 3, 2023
65. Achilles JS, Castaneda-Lovato J. A quality improvement initiative to improve the care of infants born exposed to opioids by implementing the eat, sleep, console assessment tool. *Hosp Pediatr*. 2019;9(8):624–631
66. Parlaman J, Deodhar P, Sanders V, Jerome J, McDaniel C. Improving care for infants with neonatal abstinence syndrome: a multi-center, community hospital-based study. *Hosp Pediatr*. 2019;9(8):608–614
67. Morrison TM, MacMillan KDL, Melvin P, et al. Neonatal opioid withdrawal syndrome: a comparison of as-needed pharmacotherapy. *Hosp Pediatr*. 2022;12(5):530–538
68. NIH Heal Initiative. The OPTimize NOW Study. Available at: <https://helpfornows.rti.org/general/optimizeNOW/joinus>. Accessed May 14, 2023
69. Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus methadone for opioid use disorder in pregnancy. *N Engl J Med*. 2022;387(22):2033–2044
70. Krans EE. Neonatal outcomes after use of buprenorphine during pregnancy. *N Engl J Med*. 2022;387(22):2085–2086
71. Straub L, Huybrechts KF, Hernández-Díaz S, et al. Trajectories of prescription opioid utilization during pregnancy among prepregnancy chronic users and risk of neonatal opioid withdrawal syndrome. *Am J Epidemiol*. 2022;191(1):208–219
72. Singh R, Houghton M, Melvin P, et al. fPNQIN Collaborative of Massachusetts. Predictors of pharmacologic therapy for neonatal opioid withdrawal syndrome: a retrospective analysis of a statewide database. *J Perinatol*. 2021;41(6):1381–1388
73. Devlin LA, Hu Z, Ounpraseuth S, et al. The influence of mediators on the relationship between antenatal opioid agonist exposure and the severity of neonatal opioid withdrawal syndrome. *Matern Child Health J*. 2023;27(6):1030–1042
74. Morris E, Bardsley T, Schulte K, et al. Hospital outcomes of infants with neonatal opioid withdrawal syndrome at a tertiary care hospital with high rates of concurrent nonopioid (polysubstance) exposure. *Am J Perinatol*. 2022;39(4):387–393
75. Bakhireva LN, Sparks A, Herman M, Hund L, Ashley M, Salisbury A. Severity of neonatal opioid withdrawal syndrome with prenatal exposure to serotonin reuptake inhibitors. *Pediatr Res*. 2022;91(4):867–873
76. Bhatt-Mehta V, Richards J, Sturza J, Schumacher RE. Impact of in-utero exposure to selective serotonin reuptake inhibitors and opioids on neonatal opioid withdrawal syndrome. *J Addict Med*. 2019;13(3):227–234
77. Sanlorenzo LA, Cooper WO, Dudley JA, Stratton S, Maalouf FI, Patrick SW. Increased severity of neonatal abstinence syndrome associated with concomitant antenatal opioid and benzodiazepine exposure. *Hosp Pediatr*. 2019;9(8):569–575
78. Bibi S, Gaddis N, Johnson EO, et al. Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome. *Pediatr Res*. 2023;93(5):1368–1374
79. Radhakrishna U, Vishweswaraiah S, Uppala LV, et al. Placental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome. *Genomics*. 2021;113(3):1127–1135
80. Mahnke AH, Roberts MH, Leeman L, Ma X, Bakhireva LN, Miranda RC. Prenatal opioid-exposed infant extracellular miRNA signature obtained at birth predicts severity of neonatal opioid withdrawal syndrome. *Sci Rep*. 2022;93(5):1368–137

81. Borrelli KN, Wachman EM, Beierle JA, et al. Effect of prenatal opioid exposure on the human placental methylome. *Biomedicines*. 2022;10(5):1150
82. Crook TW, Munn EK, Scott TA, et al. Improving the discharge process for opioid-exposed neonates. *Hosp Pediatr*. 2019;9(8):643–648
83. Goyal NK, Rohde JF, Short V, Patrick SW, Abatemarco D, Chung EK. Well-child care adherence after intrauterine opioid exposure. *Pediatrics*. 2020;145(2):e20191275
84. Peacock-Chambers E, Leyenaar JK, Foss S, et al. Early intervention referral and enrollment among infants with neonatal abstinence syndrome. *J Dev Behav Pediatr*. 2019;40(6):441–450
85. Liu G, Kong L, Leslie DL, Corr TE. A longitudinal health care use profile of children with a history of neonatal abstinence syndrome. *J Pediatr*. 2019;204:111–117.e1
86. Corr TE, Xing X, Liu G. Longitudinal health care utilization of Medicaid-insured children with a history of neonatal abstinence syndrome. *J Pediatr*. 2021;233:82–89.e1
87. Percy Z, Brokamp C, McAllister JM, Ryan P, Wexelblatt SL, Hall ES. Subclinical and overt newborn opioid exposure: prevalence and first-year health care utilization. *J Pediatr*. 2020;222:52–58.e1
88. Leyenaar JK, Schaefer AP, Wasserman JR, Moen EL, O'Malley AJ, Goodman DC. Infant mortality associated with prenatal opioid exposure. *JAMA Pediatr*. 2021;175(7):706–714
89. Grossarth S, Osmundson SS, Wiese AD, et al. Maternal opioid use disorder and the risk of postneonatal infant mortality. *JAMA Pediatr*. 2023;177(7):675–683
90. Bann CM, Newman JE, Poindexter B, et al. Outcomes of babies with opioid exposure (OBOE): protocol of a prospective longitudinal cohort study. *Pediatr Res*. 2023;93(6):1772–1779
91. NIH HEAL Initiative. HEALTHy Brain and Child Development Study (HBCD). Available at: <https://heal.nih.gov/research/infants-and-children/healthy-brain>. Accessed April 18, 2023
92. Lee SJ, Bora S, Austin NC, Westerman A, Henderson JMT. Neurodevelopmental outcomes of children born to opioid-dependent mothers: a systematic review and meta-analysis. *Acad Pediatr*. 2020;20(3):308–318
93. Yeoh SL, Eastwood J, Wright IM, et al. Cognitive and Motor outcomes of children with prenatal opioid exposure: a systematic review and meta-analysis. *JAMA Netw Open*. 2019;2(7):e197025
94. Schwartz AN, Reyes LM, Meschke LL, Kintziger KW. Prenatal opioid exposure and ADHD childhood symptoms: a meta-analysis. *Children (Basel)*. 2021;8(2):106
95. Czyski AJ, Davis JM, Dansereau LM, et al. Neurodevelopmental outcomes of neonates randomized to morphine or methadone for treatment of neonatal abstinence syndrome. *J Pediatr*. 2020;219:146–151.e1
96. ClinicalTrials.gov. ACT NOW longitudinal study: Outcomes of Babies with Opioid Exposure Study (OBOE). Available at: <https://beta.clinicaltrials.gov/study/NCT04149509?distance=50&id=NCT04149509&rank=1>. Accessed April 18, 2023
97. Benninger KL, McAllister JM, Merhar SL. Neonatal opioid withdrawal syndrome: an update on developmental outcomes. *Clin Perinatol*. 2023;50(1):17–29
98. Individuals With Disabilities Education Act, 20 U.S.C. & Part C. 2004
99. National Archives. 34 CFR Part 303, 303.21(b), 303.5. Available at: <https://www.ecfr.gov/current/title-34/subtitle-B/chapter-III/part-303>. Accessed May 3, 2023
100. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing and treating hepatitis C. Available at: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCVGuidance_October_24_2022.pdf. Accessed April 15, 2023
101. Panagiotakopoulos L, Sandul AL, et al. CDC recommendations for hepatitis C testing among perinatally exposed infants and children — United States, 2023. *MMWR Recomm Rep*. 2023;72(4):1–19
102. Hemmati Z, Conti AA, Baldacchino A. Ophthalmic outcomes in children exposed to opioid maintenance treatment in utero: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2022;136:104601
103. US Food and Drug Administration. 21st Century Cures Act. Available at: <https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act>. Accessed April 30, 2023
104. Shan F, MacVicar S, Allegaert K, et al. Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review. *Trials*. 2020;21(1):262
105. Kelly LE, Shan F, MacVicar S, et al. A core outcome set for neonatal opioid withdrawal syndrome. *Pediatrics*. 2020;146(1):e20200018